ribociclib succinate : A New Option for Advanced Breast Cancer

ribociclib succinate has emerged as a globally recognized treatment for HR+/HER2- metastatic breast cancer, particularly in premenopausal and postmenopausal patients. This innovative drug offers extended survival and reduced disease progression compared to traditional chemotherapy.

How ribociclib succinate Works

ribociclib succinate works by inhibiting CDK4/6 proteins, which are crucial in cell growth and division. By targeting these proteins, Ribociclib effectively slows the progression of cancer cells, helping patients manage their condition more effectively.

The use of ribociclib succinate in the treatment of metastatic breast cancer.

ribociclib succinate is used in conjunction with hormone therapy (Endocrine Therapy) such as Letrozole, Anastrozole, or Fulvestrant in premenopausal patients. Goserelin injections are required to stop the production of hormones from the ovaries. Treatment with Ribociclib can help.

Prolongs survival without progression of disease. (Progression-Free Survival or PFS)
Reduced risk of progression compared to chemotherapy.
Reduces the incidence of serious side effects compared to chemotherapy drugs.

Indications for use of ribociclib succinate

Ribociclib is indicated for the treatment of hormone receptor-positive (HR+) and HER2-negative breast cancer in patients with advanced stage breast cancer. spread or spread Especially in the following cases:

Premenopausal or postmenopausal patients: This medication can be used together with hormone therapy such as letrozole, anatrozole, or fulvestrant. The drug goserelin must be added to suppress hormones in premenopausal patients.
Patients who have not previously received systemic therapy for metastatic breast cancer: Ribociclib is usually used as first-line treatment for previously untreated HR+/HER2- breast cancer.
Use of medicines with hormone therapy (Endocrine Therapy): Ribociclib is often used together with hormone medicines to help control the growth of cancer cells. By inhibiting CDK4/6 proteins, which are important factors in cancer cell division.
Aggressive Disease: Used in patients with cancer that has spread to internal organs. or there is rapid growth of cancer cells

Ribociclib prolongs progression-free survival compared with chemotherapy and is widely used in patients who respond well to hormone therapy.

Study results show ribociclib succinate is better than chemotherapy.

Patients on Ribociclib + Endocrine Therapy had a median PFS of 24 months, compared to 12.3 months in the chemotherapy group.
The risk reduction rate of disease progression (Hazard Ratio, HR) was 0.54.
The statistical probability value (P-value) is 0.0007, which confirms the reliability of the study results.

Side effects you should know

Patients using ribociclib succinate may experience side effects such as:

Fatigue
Nausea and vomiting
abnormal liver function
changes in blood cell levels

Therefore, it is important to regularly monitor your symptoms and consult your doctor.

ribociclib succinate is a groundbreaking treatment for HR+/HER2- metastatic breast cancer. By providing longer survival times and a better quality of life, Kisqali serves as an effective alternative to traditional chemotherapy. If you or a loved one is battling breast cancer, consult your doctor to explore treatment options that are best suited to your needs.